Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes.
about
Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumoursThrombopoietin mimetics for patients with myelodysplastic syndromesEltrombopag for the treatment of aplastic anemia: current perspectivesAlternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia.Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.Romiplostim in the management of thrombocytopenia in a patient with autoimmune hepatitis.A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide.Pathogenesis and management of inherited thrombocytopenias: rationale for the use of thrombopoietin-receptor agonists.Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.The pharmacology and clinical application of thrombopoietin receptor agonists.Thrombopoiesis-stimulating agents and myelodysplastic syndromes.Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients.Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic reviewRomiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.Current therapy of myelodysplastic syndromesThe revolution of myelodysplastic syndromes.Romiplostim dose-response in patients with myelodysplastic syndromesDiagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.Thrombopoietin mimetics for patients with myelodysplastic syndromes.Personalized treatment strategies for elderly patients with myelodysplastic syndromes.Thrombocytopenia in Patients with Myelodysplastic Syndromes: Still an Unsolved Problem.
P2860
Q24186714-ECA36937-7433-4BB2-9D24-F6D2247BC32BQ24198060-9FA4A4FF-CFF5-42FA-A7EB-2BCCB978E7B8Q28071710-AFCE8A83-DDC5-43CB-BDCA-C7054C08EBC9Q30248355-73885FB3-9E0F-47CF-9F8D-BEDB40D9CB8AQ33398217-B269CC32-5EE8-4507-B1B4-7DBFAB54001CQ33398815-DC4FA6A7-61BC-44B2-B260-5FC6C8A373C3Q33402513-A8BEE0BD-E8D2-4F2B-9EAC-157B3F73E48CQ33402882-20AE02FC-0D27-49D3-A905-B5A63DFC2063Q33404600-BA5F2FF1-E4DF-481B-A7E7-92CBF0EFE52EQ33407443-E4B2D9F5-73D7-42D0-82C6-1C710EDA5D6BQ33414453-FA4FD376-C54E-49CB-A0CC-BCEBED7B1508Q33416541-1567178E-A277-4125-9CA0-01E9EF09D825Q33417700-A6B60938-48AC-4376-9E89-125D0896ADE9Q33420207-1B49417B-3270-457D-BA59-FD4D99529002Q33426772-4722599F-27A8-405A-88A2-C673C5B451AFQ33436416-6878647C-4459-4662-8DD0-15E0C3E4CABEQ33442715-0AC37FB6-21F3-48C6-A245-4197FA298181Q34013796-0371F1FB-032C-4EAC-BFDC-AC5301D32BCEQ36612553-F4379145-62F2-4039-97A7-C66E1DFE73B1Q36948110-9E446F94-50A6-4233-856B-7F0AE5997599Q37263146-7FF4BC7B-2DBF-4692-9165-BF45EA33F0FFQ47409875-F36862AB-9B2A-499C-B0CC-4EF5DB72F3EBQ47550396-4AC2DC38-7780-4933-AE89-AA6226DACFDBQ50083438-2B5CE845-AB21-4C47-96C1-E9A46BE3DD3FQ55666053-88020DFA-6E57-4296-B2ED-70CE1FAF6393
P2860
Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Subcutaneous or intravenous ad ...... isk myelodysplastic syndromes.
@ast
Subcutaneous or intravenous ad ...... isk myelodysplastic syndromes.
@en
type
label
Subcutaneous or intravenous ad ...... isk myelodysplastic syndromes.
@ast
Subcutaneous or intravenous ad ...... isk myelodysplastic syndromes.
@en
prefLabel
Subcutaneous or intravenous ad ...... isk myelodysplastic syndromes.
@ast
Subcutaneous or intravenous ad ...... isk myelodysplastic syndromes.
@en
P2093
P2860
P356
P1433
P1476
Subcutaneous or intravenous ad ...... isk myelodysplastic syndromes.
@en
P2093
Adam Boruchov
Agnes Guerci-Bresler
Dietmar Berger
Janet Franklin
Kuolung Hu
Mikkael A Sekeres
Pamela Becker
Yow-Ming C Wang
P2860
P304
P356
10.1002/CNCR.25545
P407
P577
2010-10-13T00:00:00Z